RESUMEN
The effects of the new progestagen desogestrel on the changes induced by ethinyloestradiol (EE) on the serum levels of sex hormone binding globulin (SHBG), transcortin, ceruloplasmin and haptoglobin were studied in healthy female volunteers. Desogestrel (0.125 mg or 0.250 mg) administered in combination with 0.050 mg EE was compared with 0.050 mg EE alone. After 7 and 14 days the three regimens induced similar changes in the serum levels of transcortin, ceruloplasmin and haptoglobin. Desogestrel at a dose level used in oral contraceptives did not inhibit the EE-induced increase in SHBG capacity while its influence on this parameter at twice the clinical dosage (0.250 mg) used was still minor. It can be concluded that with respect to the parameters studied desogestrel in the clinical dosage used has no detectable oestrogenic or androgenic effect.
Asunto(s)
Proteínas Sanguíneas/metabolismo , Etinilestradiol/farmacología , Norpregnenos/farmacología , Adulto , Ceruloplasmina/metabolismo , Desogestrel , Combinación de Medicamentos , Femenino , Haptoglobinas/metabolismo , Humanos , Globulina de Unión a Hormona Sexual/metabolismo , Transcortina/metabolismoAsunto(s)
Endometrio/efectos de los fármacos , Estrenos/farmacología , Etinilestradiol/farmacología , Ovario/efectos de los fármacos , Ovulación/efectos de los fármacos , Adenohipófisis/efectos de los fármacos , Congéneres de la Progesterona/farmacología , Adulto , Temperatura Corporal/efectos de los fármacos , Ensayos Clínicos como Asunto , Combinación de Medicamentos , Evaluación de Medicamentos , Endometrio/citología , Estradiol/sangre , Estrenos/administración & dosificación , Estrenos/efectos adversos , Etinilestradiol/administración & dosificación , Etinilestradiol/efectos adversos , Femenino , Hormona Folículo Estimulante/sangre , Homoesteroides/administración & dosificación , Homoesteroides/efectos adversos , Homoesteroides/farmacología , Humanos , Hígado/efectos de los fármacos , Pruebas de Función Hepática , Hormona Luteinizante/sangre , Progesterona/sangre , Congéneres de la Progesterona/administración & dosificación , Congéneres de la Progesterona/efectos adversos , Prolactina/sangreRESUMEN
A study was carried out in 9 women volunteers to investigate the centron of 0.75 mg lynestrenol plus 0.0375 mg ethinyl oestradiol given for 22 days per cycle over a period of 6 cycles. The results of assessments of a number of hormonal, vaginal and cervical parameters showed that this combination has a two-fold effect: a central effect on the pituitary and a peripheral effect on the ovaries and on endometrial development. The findings of an effect on cervical mucus, as with higher dose combinations, were not sufficiently consistent to warrant a claim for a cervical barrier. The preparation appeared to be well tolerated but there was a high incidence of irregular bleeding in the first treatment cycle. In most of the women, however, this had corrected itself by the second cycle.
PIP: A study was carried out in 9 women volunteers to investigate the central and peripheral effects of a low-dosage oral contraceptive combination of .75 mg lynestrenol plus .0375 mg ethinyl estradiol given for 22 days per cycle over a period of 6 cycles. The results of assessments of a number of hormonal, vaginal, and cervical parameters showed that this combination has a 2-fold effect: a central effect on the pituitary and a peripheral effect on the ovaries and on endometrial development. The findings of an effect on cervical mucus, as with higher dose combinations, were not sufficiently consistent to warrant a claim for a cervical barrier. The preparation appeared to be well tolerated but there was a high incidence of irregular bleeding in the 1st treatment cycle. In most of the women, however, this had corrected itself by the 2nd cycle.